Mazdutide is an investigational dual-agonist peptide studied for its activity at:
GLP-1 (glucagon-like peptide-1) receptors
Glucagon receptors
Because it engages two complementary metabolic pathways, Mazdutide is researched for how combined signaling influences energy balance, glucose regulation, and body-weight–related metabolic processes.
It is not an approved medication and remains a research-only compound.
Mazdutide is designed to simultaneously activate GLP-1 and glucagon pathways, which play distinct but interconnected roles in metabolism:
Involved in appetite signaling and satiety pathways
Modulates glucose-related signaling
Influences gastric emptying and central metabolic regulation
Promotes energy expenditure pathways
Supports lipid utilization and hepatic metabolic signaling
Counterbalances some GLP-1 effects to avoid excessive energy suppression
The dual-agonist design aims to reduce intake-driven signals while supporting energy expenditure, creating a more balanced metabolic response in research models.
Studied for coordinated control of intake and expenditure pathways
Differs from single-receptor agonists by targeting both sides of the energy equation
Encourages shifts in substrate utilization (glucose vs fat)
Supports adaptive metabolic responses in preclinical studies
Acts on central appetite-related pathways
Also influences peripheral metabolic organs such as the liver
Glucagon activity may help offset metabolic suppression sometimes seen with GLP-1–only signaling in research models
